Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
Lead Sponsor:
ConjuChem
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
25+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in pa...
Eligibility Criteria
Inclusion
- Major Inclusion Criteria:
- BMI: 27 to 45 kg/m2
- Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator
- Stable life-style, i.e. diet \& physical activity, as determined by the Investigator
- Stable metformin daily dose ≥1000 mg for at least 3 months
- Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%
Exclusion
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00638716
Start Date
February 1 2008
End Date
November 1 2008
Last Update
June 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ConjuChem Biotechnologies Inc.
Montreal, Quebec, Canada, H2X 3Y8